https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004827-29
EudraCT Number: 2014-004827-29
Sponsor Protocol Number: VX14-661-110
Sponsor Name: Vertex Pharmaceuticals Incorporated
Start Date: 2015-09-01
Medical condition: Cystic Fibrosis
Disease:
Version: 18.0
SOC Term: 10010331 – Congenital, familial and genetic disorders
Classification Code: 10011762
Term: Cystic fibrosis
Level: PT
Population Age: Adolescents, Under 18, Adults
Gender: Male, Female
Trial Protocol: IT (Ongoing), IE (Ongoing), GB (Ongoing), BE (Ongoing), SE (Ongoing), AT (Completed), DK (Ongoing), NL (Ongoing), DE (Ongoing), ES (Completed)
A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, …
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004827-29
Last Update Posted: 05/06/19 11:34AM
